The Board of Eliem Therapeutics, Inc. has approved a corporate reorganization plan to conserve financial resources. As part of the reorganization, the Company will reduce its workforce by approximately 55% in the first half of 2023. In connection with this reorganization, Bob Azelby, chief executive officer will be departing the Company and the Board imminently.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.66 USD | +3.37% | -2.30% | +183.70% |
May. 15 | Eliem Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Apr. 11 | Sector Update: Health Care Stocks Softer Late Afternoon | MT |
1st Jan change | Capi. | |
---|---|---|
+183.70% | 216M | |
+9.83% | 118B | |
+10.80% | 106B | |
-10.84% | 23.4B | |
-1.69% | 22.1B | |
-10.23% | 18.34B | |
-41.92% | 16.59B | |
-15.11% | 15.97B | |
+6.62% | 14.03B | |
+17.53% | 11.67B |
- Stock Market
- Equities
- ELYM Stock
- News Eliem Therapeutics, Inc.
- Bob Azelby to Depart as Chief Executive Officer of Eliem Therapeutics, Inc